Last updated: February 16, 2026
What is the current market status of NDC 00597-0355?
NDC 00597-0355 refers to Veklury (remdesivir), developed by Gilead Sciences, approved for treatment of COVID-19. Its market has stabilized since the peak of the pandemic, with steady sales driven by regulatory approvals and inclusion in treatment guidelines.
As of 2023, remdesivir remains the only FDA-approved antiviral for COVID-19 in hospitalized patients. It has also gained single-drug or combination use in several countries, including the EU and Japan. Market penetration is highest within hospital settings and outpatient infusion programs.
Global sales revenue for remdesivir was approximately $5.1 billion in 2022, down from a peak of $7.5 billion in 2021 during the height of COVID-19 surges, reflecting evolving treatment protocols and competition from newer antivirals.
How competitive is the remdesivir market?
The remdesivir market faces competition primarily from oral antivirals such as:
- Pfizer's Paxlovid (nirmatrelvir/ritonavir)
- Merck's Lagevrio (molnupiravir)
These oral agents typically are prescribed early in the infection course, reducing hospitalization rates. Their convenience and lower administration requirements limit remdesivir's use primarily to hospital settings.
Market shares are estimated as follows:
| Drug |
2022 Market Share |
Main Use Case |
| Remdesivir |
55% |
Hospitalized, severe COVID-19 |
| Paxlovid |
30% |
Mild-to-moderate outpatient |
| Molnupiravir |
15% |
Outpatient, alternative |
The decline in remdesivir's market share indicates shift toward oral antivirals and primary treatment moves to early-stage outpatient therapy.
What are the key price projections for remdesivir?
Pricing varies by payer, region, and dosing course:
- U.S. retail price per treatment course: approximately $2,340 to $3,120 for a 5-day IV treatment.
- Government procurement prices: often lower due to negotiated discounts, averaging around $1,600 to $2,200 per course.
Future price trends depend on factors like:
- Generic entry: Remdesivir patents are set to expire in several jurisdictions starting in 2024, potentially leading to generic versions that could reduce prices by up to 50%.
- Pricing strategies: Gilead may implement tiered pricing in emerging markets, potentially lowering prices to expand access.
Projection estimates suggest:
- 2023-2024: sales could decline by 20-30% due to market saturation, with reduced per-unit prices as generics enter.
- Post-2025: volume could decline further unless remdesivir finds new indications or is used for other viral infections, which remains unlikely based on current approval status.
Are there regulatory or policy factors influencing remdesivir pricing?
Yes. Policies in major markets influence pricing:
- United States: CDC's continued recommendation and strategic stockpiling support sustained demand.
- European Union: Reimbursement policies and national procurement agreements impact retail prices.
- Affordable access programs: Gilead's licensing agreements aim to supply generics in low-income countries at lower prices, ranging from $10 to $100 per dose.
Patent expiration is expected to enable significant price reductions globally over the next two years, impacting overall revenue.
What are the commercial prospects?
Remdesivir's market is shrinking with the adoption of oral antivirals and updated COVID-19 treatment protocols emphasizing outpatient therapy. The overall opportunity for new sales hinges on:
- New clinical evidence that supports expanded indications.
- Development of new formulations or combination therapies.
- Regulatory approvals in pediatric populations or for other serious viral illnesses, which are under evaluation but unlikely to materially alter the revenue base in the near term.
Gilead's near-term focus is on licensing and generic manufacturing partnerships to expand access in emerging markets, with limited upside in developed markets unless new indications are authorized.
Summary table of market metrics
| Year |
Global Sales (USD billion) |
Major Competitors |
Price Range per Course (USD) |
Patent Status |
| 2021 |
7.5 |
Paxlovid, Molnupiravir |
$2,340–$3,120 |
Patent exclusivity until 2024 (US/IP rights in key jurisdictions) |
| 2022 |
5.1 |
Paxlovid, Molnupiravir |
$1,600–$2,200 (govt. prices) |
Patent expiration approaching (2024–2026) |
| 2023 |
~3.6 (projected) |
Paxlovid, Molnupiravir |
Reduced with generic entry |
Patent expiry imminent in some markets |
Key Takeaways
- The remdesivir market is mature with declining sales driven by competition from oral antivirals.
- Price projections forecast a 20-30% decrease in revenue through 2024, fueled by patent expiry and generic competition.
- Market share is shifting toward outpatient therapies, limiting remdesivir’s role predominantly to hospital settings.
- Certification for expanded indications remains unlikely to impact revenue significantly.
- Future growth depends on licensing agreements, development of new formulations, and global access expansion.
FAQs
-
When will generic versions of remdesivir become available?
Patent expirations are expected in several jurisdictions starting in 2024, enabling generic manufacturing.
-
What regional factors affect remdesivir pricing?
Pricing is influenced by government procurement strategies, reimbursement policies, and licensing agreements, with lower prices in emerging markets due to licensing.
-
Are there any new indications being explored for remdesivir?
Current focus is limited; ongoing studies are assessing its use in other viral infections but no major expansion is anticipated soon.
-
How does remdesivir compare with oral antivirals?
Oral antivirals like Paxlovid and Molnupiravir are more convenient, have higher market share for outpatient use, and are expected to continue replacing remdesivir outside hospital settings.
-
What is the long-term outlook for remdesivir?
Market decline is inevitable without new indications or formulations. Revenue will primarily come from ongoing hospital use and licensing in developing countries.
Sources
[1] Gilead Sciences. (2022). Annual Report.
[2] IQVIA. (2023). Global Vaccines & Infectious Disease Market Trends.
[3] U.S. FDA. (2020). Remdesivir approval and updates.
[4] European Medicines Agency. (2022). Remdesivir assessment report.
[5] Bloomberg Intelligence. (2023). COVID-19 Antiviral Market Analysis.
